Ussia Gian Paolo, Cammalleri Valeria, Marchetti Andrea Ascoli, Sarkar Kunal, De Vico Pasquale, Muscoli Saverio, Sergi Domenico, Marchei Massimo, Ippoliti Arnaldo, Romeo Francesco
aDepartment of Cardiovascular Disease bDepartment of Vascular Surgery cDepartment of Anaesthesiology, University of Rome Tor Vergata, Rome, Italy.
J Cardiovasc Med (Hagerstown). 2015 Apr;16(4):271-8. doi: 10.2459/JCM.0000000000000063.
We describe an alternative access approach for patients undergoing transcatheter aortic valve implantation (TAVI) using surgical cut down of the distal axillary artery, in cases wherein transfemoral access is not feasible.
From January 2012 to July 2013, 61 patients (59% men; mean age 81 ± 8 years) underwent TAVI at our institution. The mean logistic EuroSCORE and EuroSCORE II were 36 ± 24 and 14 ± 10, respectively. We assessed device success, 30-day safety and clinical efficacy using VARC II criteria.
TAVI was performed with the CoreValve Revalving System (CRS) (Medtronic Inc., Minneapolis, Minnesota, USA) in all cases, using transfemoral approach in 57 patients and distal trans-axillary route in four patients. A device was successfully implanted in 94%, without any major intraprocedural complications. One case of acute kidney disease, four cases of minor vascular complication and two cases of life-threatening bleeding occurred after the procedure for pericardial bleeding requiring pericardiocentesis. Permanent pacemaker was implanted in 26% of patients. There was no instance of in-hospital mortality, while two deaths (3%) occurred in the first 30 days. The total procedure time (skin-to-skin) was longer in the trans-axillary group secondary to surgical management of access site (P = 0.027), whereas revalving and fluoroscopy time were similar (P = 0.95 and P = 0.83, respectively).
The location and anatomical relations of the distal axillary artery make it a safer, reproducible and operator friendly access option for TAVI.
我们描述了一种在经股动脉入路不可行的情况下,通过外科切开腋动脉远端为行经导管主动脉瓣植入术(TAVI)的患者提供的替代入路方法。
2012年1月至2013年7月,61例患者(59%为男性;平均年龄81±8岁)在我们机构接受了TAVI。平均逻辑欧洲心脏手术风险评估系统(EuroSCORE)和欧洲心脏手术风险评估系统II(EuroSCORE II)分别为36±24和14±10。我们使用瓣膜学术研究联合会(VARC)II标准评估手术成功率、30天安全性和临床疗效。
所有病例均使用美敦力公司(美国明尼苏达州明尼阿波利斯)的CoreValve Revalving System(CRS)进行TAVI,57例患者采用经股动脉入路,4例患者采用经腋动脉远端入路。94%的患者成功植入了器械,术中无任何重大并发症。术后发生1例急性肾疾病、4例轻微血管并发症和2例因心包出血需要心包穿刺的危及生命的出血。26%的患者植入了永久性起搏器。住院期间无死亡病例,30天内有2例死亡(3%)。由于入路部位的外科处理,经腋动脉组的总手术时间(皮肤到皮肤)较长(P = 0.027),而瓣膜置换和透视时间相似(分别为P = 0.95和P = 0.83)。
腋动脉远端的位置和解剖关系使其成为TAVI一种更安全、可重复且对术者友好的入路选择。